Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.​

2020's Premium Sponsors of the Next Gen Omics Series UK Include:

Sponsor

Sponsors

Sponsors

Why Sponsor With Us?

Oxford Global organise events with a clear vision – to directly connect industry leaders with companies offering relevant solutions. There are three ways in which we achieve this;

Size – Whether hosting 100 or 1000 delegates, our aim is to create an intimate & engaging setting in which to create conversations of value.

Decision Makers – We understand that events provide valuable face to face time with prospects. Our aim is to put you in the room with key decision makers who can provide insight into their company’s goals, challenges and requirements.

Networking – Alongside the strong scientific programme, we ensure that there are plenty of opportunities to engage with delegates. With networking lunches, drinks receptions and popular roundtables, we provide you with invaluable time to network. You can expect at least seven hours of networking at each of our events.

Thought Leadership

  • Workshops
  • Presentations
  • Hosted Panels & Roundtables
  • Breakout Sessions

Business Development & Lead Generation

  • 1-2-1 Meetings
  • Hosted Dinners & Private Functions
  • Lead Retrieval/Badge Scanning

Brand Visibility

  • Exhibition
  • Sponsored Functions
  • Branded Event Materials
  • Event App Sponsorship

Knowledge Sharing

  • Hosted Webinars
  • Pre & Post Event Content Delivery

Live Webinar

Genomic Testing Strategies For Research Through To Clinical Studies: Profiling Of Genomics From NeoGenomics' Perspective

As genomic technologies develop and mature, adoption moves from the research environment into the clinical setting.  Previously, where Sanger and qPCR were the most rational choices to commercialize a diagnostic, NGS has become the biomarker testing methodology of choice.  Additionally, other emerging technologies and platforms like NanoString are finding their way into clinical trials as well as routine diagnostics.  With advances in technology, biomarker testing strategies have also evolved with a trend toward higher order multiplexed technologies as well as cross modality testing from a single sample to understand correlations between DNA, RNA and protein markers.  More data may be over burdensome to analyze, while a focused assay may miss an opportunity for collecting potentially valuable data.  Without a straightforward “rule of thumb” for which genomics technology to use when, thoughtful consultation is required.  This presentation will discuss the various factors and consideration points for choosing a genomic biomarker testing strategy to support biomarker projects.

Presented by James Yen, Senior Scientific Manager, CDx Programs, NeoGenomics

Thursday, 25 June 2020 | 15:30 BST